Ocugen (OCGN) Cash & Equivalents (2014 - 2026)
Ocugen's (OCGN) quarterly Cash & Equivalents came in at $37.8 million in Q1 2025, up 43.32% YoY from $26.4 million in Q1 2024, and up 140.81% on a QoQ basis from $15.7 million in Q2 2024.
Ocugen (OCGN) Cash & Equivalents (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 12 years of Cash & Equivalents data on file, last reported at $37.8 million in Q1 2025.
- Quarterly Cash & Equivalents rose 43.32% year-over-year to $37.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $37.8 million (up 43.32% YoY) and the FY2023 annual result came in at $39.5 million, down 49.12% from the prior year.
- Cash & Equivalents rose to $37.8 million in Q1 2025, from $15.7 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $129.8 million in Q1 2022 to a low of $15.7 million in Q2 2024.
- A 5-year average of $73.2 million and a median of $70.6 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2021 — Cash & Equivalents surged 1302.82% — and 2024, when it tumbled 77.76%.
- Tracing OCGN's Cash & Equivalents over 5 years: stood at $95.0 million in 2021, then declined by 18.32% to $77.6 million in 2022, then plunged by 49.12% to $39.5 million in 2023, then plunged by 60.22% to $15.7 million in 2024, then surged by 140.81% to $37.8 million in 2025.
- The last three Cash & Equivalents figures came in at $37.8 million (Q1 2025), $15.7 million (Q2 2024), and $26.4 million (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 100.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.10 Mn |
| Dec 31, 2025 | 18.57 Mn |
| Jun 30, 2025 | 27.01 Mn |
| Mar 31, 2025 | 37.80 Mn |
| Jun 30, 2024 | 15.70 Mn |
| Mar 31, 2024 | 26.38 Mn |
| Dec 31, 2023 | 39.46 Mn |
| Sep 30, 2023 | 53.48 Mn |
| Jun 30, 2023 | 70.58 Mn |
| Mar 31, 2023 | 68.26 Mn |
| Dec 31, 2022 | 77.56 Mn |
| Sep 30, 2022 | 101.60 Mn |
| Jun 30, 2022 | 115.01 Mn |
| Mar 31, 2022 | 129.77 Mn |
| Dec 31, 2021 | 94.96 Mn |
| Sep 30, 2021 | 107.35 Mn |
| Jun 30, 2021 | 115.64 Mn |
| Mar 31, 2021 | 44.79 Mn |
| Dec 31, 2020 | 24.04 Mn |
| Sep 30, 2020 | 19.11 Mn |